This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.

Jon Kaiser

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

JonD. Kaiser, MD, is a Clinical Associate at the University of California at San Francisco School of Medicine[1], a past board member of International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[2], previous Medical Director of K-PAX Pharmaceuticals[3], and a physician in private practice specializing in integrative medicine and the treatment of people with diseases of the nervous and immune systems.

Dr. Kaiser personally suffered from ME/CFS for over fifteen years. "It took me five years to recover to the point where I was close to normally functional. If I worked too hard, if some sort of stress occurred that I couldn't avoid, I would have a relapse lasting days to weeks," Kaiser said. "One of the things that got me interested in micronutrients and supplements early on was using them to help support my recovery."[3] I also developed several mind-body techniques that we're extremely helpful in my recovery from ME/CFS.

As Medical Director of K-PAX Pharmaceuticals, Dr. Kaiser helped perform the Synergy Trial, a double-blind, placebo-controlled clinical trial of a new treatment designed to improve the fatigue and decreased concentration symptoms in people with Chronic Fatigue Syndrome (CFS). The treatment combines a low dosage of a prescription stimulant medication, methylphenidate hydrochloride, with broad-spectrum mitochondrial support nutrients.[4]

At the beginning of 2020, Dr. Kaiser returned to private medical practice in Mill Valley, California and currently consults with patients worldwide using telemedicine. In 2019, Dr. Kaiser wrote an E-book titled "A Healing Program for Fibro & Fatigue" that can be obtained free on his medical practice website.

Education

  • Bachelor of Science degrees in biochemistry and philosophy from the State University of New York at Binghamton.
  • MD, from University of Texas Medical School in Houston, receiving honors in Internal Medicine and Emergency Medicine.[5]

Articles

Talks and interviews

Notable studies

  • 2015, A prospective, proof-of-concept investigation of KPAX002 in chronic fatigue syndrome.[7] (Full Text)
  • 2018, KPAX002 as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A prospective, randomized trial[8] (Full Text)

Learn more

See also

References